Clinical Trials Browser

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07601178 2026-05-22

QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Breast Cancer

Phase 2 Recruiting

34 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07340541 2026-05-20

EVOLVE-BDT

Phase 2 Recruiting

700 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05115474 2026-05-18

Study of Screening Brain MRIs in Stage IV Breast Cancer

Phase 2 Recruiting

170 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07394387 2026-05-15

Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.

Phase 2 Recruiting

58 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03606967 2026-05-13

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

Phase 2 Recruiting

70 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07283692 2026-05-13

Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)

Phase 2 Recruiting

46 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04348747 2026-05-11

Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

Phase 2 Recruiting

23 enrolled

BreastCNS

Brain Neoplasms, Triple Negative Breast Neoplasms

NCT05846789 2026-05-08

SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers

Phase 2 Recruiting

168 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04771871 2026-05-07

TARMAC

Phase 2 Recruiting

42 enrolled

Breast

Breast Neoplasms, Neoplastic Cells, Circulating, Triple Negative Breast Neoplasms

NCT01042379 2026-05-06

I-SPY

Phase 2 Recruiting

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06845319 2026-05-06

NeoCARD

Phase 2 Recruiting

43 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06157892 2026-05-05

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Phase 2 Recruiting

172 enrolled

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT04434040 2026-05-04

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Phase 2 Recruiting

40 enrolled

Breast

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT04468061 2026-04-29

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Phase 2 Recruiting

110 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05570253 2026-04-27

A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer

Phase 2 Recruiting

55 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07276880 2026-04-27

P-RAD(+)TN-DCT

Phase 2 Recruiting

32 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06434064 2026-04-24

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

Phase 2 Recruiting

30 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07069595 2026-04-22

PREDICT-RD

Phase 2 Recruiting

78 enrolled

Breast

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT07378306 2026-04-21

FACT-TN

Phase 2 Recruiting

80 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05491226 2026-04-20

Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation

Phase 2 Recruiting

35 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06492759 2026-04-17

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

Phase 2 Recruiting

29 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05749588 2026-04-16

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

Phase 2 Recruiting

120 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07045311 2026-04-15

JS207 Combination Therapy in Triple-negative Breast Cancer

Phase 2 Recruiting

80 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04677816 2026-04-14

Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients

Phase 2 Recruiting

50 enrolled

Breast

Vitamin D Deficiency, Triple Negative Breast Neoplasms

NCT04768426 2026-04-13

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

Phase 2 Recruiting

40 enrolled

Breast

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT06649331 2026-04-08

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

Phase 2 Recruiting

160 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07078604 2026-04-07

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

Phase 2 Recruiting

20 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05660083 2026-04-03

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

Phase 2 Recruiting

36 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06358573 2026-04-02

Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK

Phase 2 Recruiting

61 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07017673 2026-04-02

Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer

Phase 2 Recruiting

34 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06365788 2026-04-01

ABBICAR

Phase 2 Recruiting

53 enrolled

Breast

Bulbo-Spinal Atrophy, X-Linked, Triple Negative Breast Neoplasms

NCT06768931 2026-04-01

Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer

Phase 2 Recruiting

192 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06831955 2026-03-20

LESLIE

Phase 2 Recruiting

356 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07457359 2026-03-09

NEOTRIO-2

Phase 2 Recruiting

18 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06318897 2026-03-04

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

Phase 2 Recruiting

28 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07342283 2026-03-02

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer

Phase 2 Recruiting

30 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03808337 2026-02-27

Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

Phase 2 Recruiting

145 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms

NCT06802757 2026-02-25

PRISM-TNBC

Phase 2 Recruiting

72 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06976944 2026-02-23

PRELUDE

Phase 2 Recruiting

44 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04683679 2026-02-17

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

Phase 2 Recruiting

34 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06291064 2026-02-17

TARMAC

Phase 2 Recruiting

85 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07188246 2026-02-11

BRINK

Phase 2 Recruiting

40 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07401537 2026-02-10

Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer

Phase 2 Recruiting

416 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05528133 2026-02-09

Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer

Phase 2 Recruiting

86 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07351487 2026-01-20

Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)

Phase 2 Recruiting

37 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06353997 2026-01-15

Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients

Phase 2 Recruiting

12 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06682195 2026-01-14

Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)

Phase 2 Recruiting

35 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07327021 2026-01-08

NOGA

Phase 2 Recruiting

54 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06690840 2026-01-05

AZALEA

Phase 2 Recruiting

45 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

DIAMOND

QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Breast Cancer

EVOLVE-BDT

Study of Screening Brain MRIs in Stage IV Breast Cancer

Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)

Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers

TARMAC

I-SPY

NeoCARD

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer

P-RAD(+)TN-DCT

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

PREDICT-RD

FACT-TN

Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

JS207 Combination Therapy in Triple-negative Breast Cancer

Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK

Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer

ABBICAR

Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer

LESLIE

NEOTRIO-2

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer

Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

PRISM-TNBC

PRELUDE

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

TARMAC

BRINK

Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer

Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer

Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)

Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients

Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)

NOGA

AZALEA